Kitashinyokohama Orthopedic Surgery

Yokohama-shi, Japan

Kitashinyokohama Orthopedic Surgery

Yokohama-shi, Japan
SEARCH FILTERS
Time filter
Source Type

Kanzaki N.,Suntory Wellness Ltd. | Izumo T.,Suntory Wellness Ltd. | Shibata H.,Suntory Wellness Ltd. | Watanabe K.,Kitashinyokohama Orthopedic Surgery | And 2 more authors.
Japanese Pharmacology and Therapeutics | Year: 2015

Objectives The objective of this study was to investigate the effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on knee joint functions in subjects with knee pain in stratified analysis based on Kellgren-Lawrence (K-L) grades. Methods A randomized, placebo-controlled, double blind intervention trial was conducted in 40 subjects with knee pain. They were randomly assigned to two groups and ingested either test supplement containing 1200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate and 45 mg quercetin glycosides (GCQ supplement) per day or placebo for 16 weeks. Stratified analysis for the result about knee joint functions evaluated by Japanese Orthopaedic Association (JOA) criteria and visual analog scales (VAS) for knee pain was conducted in subject with K-L grades ≤ I or K-L grades ≥ II. Results The result based on JOA criteria showed that change of the aggregate scores was significantly improved at week 8, 12, and 16 in the GCQ group compared to the placebo group in subject with K-L grades ≤ I, although that in subject with K-L grades ≥ II was not significantly improved. VAS for knee pain was not significantly improved in subject with K-L grades ≤ I or K-L grades ≥ II. Conclusions These results suggest that the daily supplementation of GCQ can be effective for improving knee joint functions in subjects with K-L grades ≤ I.


Kanzaki N.,Suntory Wellness Ltd. | Saito K.,Suntory Wellness Ltd. | Maeda A.,Suntory Wellness Ltd. | Kitagawa Y.,Suntory Wellness Ltd. | And 5 more authors.
Journal of the Science of Food and Agriculture | Year: 2012

Background: Oral glucosamine and chondroitin sulfate, alone and in combination, have been used worldwide for the treatment of osteoarthritis (OA), but their efficacy is controversial. This clinical study was aimed at investigating the potential of a dietary supplement containing glucosamine and chondroitin sulfate in combination with derivatives of quercetin, a naturally occurring flavonoid, (GCQ supplement) for knee OA care. Results: A randomized, double-blind, placebo-controlled study was conducted in 40 Japanese subjects with symptomatic knee OA. Subjects were randomly assigned to GCQ supplement (1200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate and 45 mg quercetin glycosides per day) or placebo and the treatment and follow-up were continued for 16 weeks. The results of symptomatic efficacy assessment based on Japanese Orthopaedic Association criteria showed that scores for two of the four symptom/function subscales, as well as the aggregate scores, were significantly improved at week 16 or earlier in the GCQ group compared to the placebo group. Moreover, analyses of cartilage metabolism biomarkers showed a trend of improvement in type II collagen synthesis/degradation balance in the GCQ group during follow-up. Conclusion: GCQ supplement was thought to be more effective than placebo in decreasing the intensity of knee OA-associated clinical symptoms. © 2011 Society of Chemical Industry.


Nagaoka I,Juntendo University | Nabeshima K.,Everlife Co. | Murakami S.,Everlife Co. | Yamamoto T.,Total Technological Consultant Co. | And 3 more authors.
Experimental and Therapeutic Medicine | Year: 2010

We aimed to investigate whether a supplementary diet containing chicken comb extract (CCE) rich in hyaluronic acid (HA) has an effect on pain and other symptoms, as well as cartilage type IIcollagen (CII) metabolism in patients with knee osteoarthritis (OA). Arandomized double-blind placebo-controlled study was conducted in 43 subjects with knee OA(Kellgren/Lawrence grade, mainly 1-2) comprising 22 patients receiving concurrent exercise therapy (ET) and 21 without ET(referred as ET-receivers and ET-unreceivers, respectively). Subjects were randomized to a CCE-containing diet (active diet) group administered a dose of 1,800 mg/day (containing 630mg of CCE and approximately 60 mg of HA) and a placebo group, and the intervention was continued for 16 weeks. Symptomatic efficacy was evaluated based on the Japanese Orthopaedic Association clinical trials response criteria (JOAresponse criteria) and visual analog scales (VAS) before (baseline) and during the intervention. To further examine its effect on CIImetabolism, the levels of two degradation biomarkers (CTX-IIand C2C) and one synthesis biomarker (CPII) were measured using urine or serum samples. Nineteen subjects (10 ET-receivers and 9 ET-unreceivers) in the active diet group and 21 subjects (10 ET-receivers and 11ET-unreceivers) in the placebo group were finally included in the study. Compared to the baseline, subscale scores of the JOAresponse criteria, i.e., 'pain/walking function', 'pain/step-up and -down function' and 'aggregate total symptoms' were more intensely improved in the active diet group than in the placebo group. Moreover, subgroup analyses of ET-receivers and ET-unreceivers indicated that significant improvements were restricted to ET-receivers of the active diet group. Furthermore, VAS assessment indicated that the 'pain on pressing' subscale was significantly improved in ET-receivers of the active diet group. In addition, analysis of CIIbiomarkers revealed that serum C2Cand CPIIlevels, but not the urinary CTX-IIlevel, were increased in the active diet group. Notably, both urinary CTX-II/serum CPIIand serum C2C/serum CPIIratios were reduced in the active diet group (particularly ET-unreceivers), suggesting that CIIsynthesis was relatively increased compared to CIIdegradation in the active diet group. Finally, no diet-related side effects were observed. The CCE-containing diet is likely to be effective in relieving symptoms in patients with knee OA. In addition, it has the potential to improve the balance of CIIdegradation/synthesis in knee OA.


Nakano M.,Chiyoda Corporation | Kamimura A.,KYOWA HAKKO BIO CO. | Watanabe F.,KYOWA HAKKO BIO CO. | Kamiya T.,KYOWA HAKKO BIO CO. | And 5 more authors.
Journal of Nutritional Science and Vitaminology | Year: 2015

Pyrroloquinoline quinone (PQQ) is a coenzyme involved in the redox-cycling system. The supplemental use of PQQ has been examined based on its properties as an antioxidant and redox modulator. Although an animal study on deficiency of PQQ suggested that PQQ contributes to skin conditions, its efficacy in humans has not been reported. The present study aimed to investigate the effects of orally administered PQQ on skin moisture, viscoelasticity, and transepidermal water loss (TEWL) both in dry skin mouse models and in healthy female subjects with a subjective symptom of dry skin. In our dry skin mouse model study, oral intake of PQQ (0.0089%, w/w, in the diet for 6 wk) significantly decreased the number of mast cells in the dermis and the number of CD3+ T-cells in the epidermis. In our human study, oral intake of PQQ (20 mg/d for 8 wk) significantly inhibited the increase in TEWL on the forearm. Finally, subject questionnaires showed positive impressions for the improvement of skin conditions. These results suggest that oral intake of PQQ improves skin conditions both in female subjects with dry skin and in mice with a compromised skin barrier function. © 2015, Center for Academic Publications Japan. All rights reserved.


Yoshimura M.,Juntendo University | Aoba Y.,Juntendo University | Watari T.,Juntendo University | Momomura R.,Juntendo University | And 11 more authors.
Experimental and Therapeutic Medicine | Year: 2012

In a previous study, we revealed that a commercially available product of dietary supplement containing a chicken comb extract (CCE), which is rich in hyaluronan, not only relieves joint pain and other symptoms, but also potentially improves the balance of type II collagen degradation/synthesis in patients with knee osteoarthritis. Since soccer is one of the sports most likely to cause knee osteoarthritis (OA), we evaluated the effect of a CCE-containing supplement on cartilage and bone metabolism in athletes. Fourteen and 15 subjects (all midfielders) were randomly assigned to receive the test product (test group) and the dummy placebo containing only vehicle (placebo group), respectively, for 12 weeks. The daily oral intake of the CCE-containing test product clearly decreased the urinary levels of both C-terminal crosslinked telopeptides of cartilage-specific type II collagen (CTX-II) as a type II collagen degradation marker and the N-terminal telopeptides of bone-specific type I collagen (NTx) as a marker of bone resorption at 12 weeks after the initiation of the intervention. By contrast, no significant reduction was detected in the placebo group at any timepoint during the intervention. These observations indicate that the test product is effective in inhibi- ting, not only cartilage degradation, but also bone remodeling. Thus, the CCE-containing supplement may be useful for the management of joint health in athletes.


Nakasone Y.,Kenkoukazoku Inc. | Watabe K.,Kenkoukazoku Inc. | Watanabe K.,Kitashinyokohama Orthopedic Surgery | Tomonaga A.,Tana Orthopedic Surgery | And 3 more authors.
Experimental and Therapeutic Medicine | Year: 2011

In the present study, we aimed to investigate the potential effect of a glucosamine (1,200 mg/day)-based dietary supplement combined with chondroitin sulfate and three antioxidant micronutrients, namely methylsulfonylmethane, guava leaf extract, and vitamin D (test supplement) on osteoarthritis (OA) of the knee. A 16-week, randomized, double-blinded, placebo-controlled trial was conducted involving 32 subjects with symptomatic knee OA. Clinical outcomes were measured using the Japanese Knee Osteoarthritis Measure (JKOM) for symptoms and a study diary-based visual analog scale (diary VAS) for pain at baseline and at weeks 4, 8, 12 and 16 during the 16-week intervention period. Furthermore, biomarkers for cartilage type II collagen degradation (C2C) and synovitis hyaluronan (HA) were measured. As compared with the baseline, the JKOM pain subscale was significantly improved at all of the four assessment time points in the test group, but was not at any time point in the placebo group. On the other hand, all of the four symptom subscales and the aggregated total symptoms were significantly improved in the two groups at one or more time points. However, all of these clinical improvements were greater in extent in the test group than in the placebo group, and there were significant differences between groups in the magnitude of changes from baseline for one subscale 'general activities' and the aggregated total symptoms at week 8 (P<0.05). The results of efficacy assessments with the diary VAS showed that all of the three pain subscales were significantly improved only in the test group at almost all the time points. Moreover, serum levels of C2C and HA were decreased by 10 and 25%, respectively, at week 16 in the test group, albeit not statistically significant, without any detectable changes in the placebo group. In conclusion, although the results obtained in this study were not conclusive, the tested glucosamine-based combination supplement is likely to have a beneficial effect on pain and other symptoms associated with knee OA.


Hattori T.,Setagaya Shizensyokuhin Co. | Murata R.,Setagaya Shizensyokuhin Co. | Fukagawa M.,Kitashinyokohama Orthopedic Surgery | Tomonaga A.,Tana Orthopedic Surgery | Nagaoka I.,Juntendo University
Japanese Pharmacology and Therapeutics | Year: 2016

Background and Objective Osteoarthritis (OA) is a representative cause of knee pain in the elderly. The estimated number of Japanese patients with knee OA is approximately 25 million. Glucosamine and chondroitin are used as a supplement to reduce the symptoms of knee pain, based on the clinical trials with knee OA patients. Thus, there is essentially no study reporting on the action of glucosamine and chondroitin-containing supplement on healthy individuals. The aim of this study was to investigate the effects of glucosamine and chondroitin sulfate on gait of healthy volunteer. Methods We conducted a randomized, placebo-controlled, double-blind, clinical trial using 60 healthy participants with weak gait ability aged 40 to 68. They were administered with a glucosamine and chondroitin-containing supplement (glucosamine hydrochloride 1200mg/day and chondroitin sulfate 60 mg/day) or a placebo for 12 weeks. The primary outcome was measured using the scores of locomo level test as well as JKOM (Japanese Knee Osteoarthritis Measure).Results In a gait ability indicator called two-step test, the score was significantly improved at 8 weeks after the intervention in the test supplement group compared with the placebo group. Furthermore, when the subjects with JKOM score>30 were analyzed, the score of two-step test was further improved in the test supplement group. These observations suggest that a test supplement improves a gait ability of the subjects with weak gait ability. Conclusions Glucosamine and chondroitin-containing supplement improves the gait ability of healthy individuals with weak gait ability.

Loading Kitashinyokohama Orthopedic Surgery collaborators
Loading Kitashinyokohama Orthopedic Surgery collaborators